BMY Stock Bristol-Myers Squibb Company
BUY US · NYSEDefensive cash flow, pipeline catalysts, and moderate valuation provide balanced upside.
Future value: $75.00 (+21.73%) · 6-12 months
Signal breakdown
- ▸Barclays and JPMorgan maintained Buy ratings.
- ▾Below 50-day MA (-2.44%)
- ▸Above 200-day MA — long-term uptrend
- ▸~22% upside to price target
Is BMY a buy right now?
Trend: BMY is trading below the 50-day average (-2.44%), RSI 47 — neutral momentum, with a 3-month return of -3.13%.
Valuation & quality: Bristol-Myers Squibb Company trades on a trailing P/E of 13.6, forward P/E 9.3, PEG 17.12, price-to-book 5.64; fundamentals show net margin 18.9%, return on equity 46.6%, revenue growth 5.7% year on year.
Analyst consensus: 24 analysts have a mean 12-month price target of $65.25 (+5.9% vs the last close; range $41.00 – $80.00), consensus rating “buy”.
Income: trailing dividend yield 4.10%.
Our screen: BUY (score 3) — Defensive cash flow, pipeline catalysts, and moderate valuation provide balanced upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -2.80% | -0.10% | -5.60% | +0.80% | +13.30% | +2.30% | -6.60% | -1.30% |
Fundamentals
Analyst price target
Technical signals
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 32,500 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.